Stagnant liquid inside an air purification unit, hundreds of complaints on tablet counts and inadequate guidance to call centers are but a few of the litany of issues outlined in the FDA’s Form 483 levied on India-based Sun Pharmaceuticals.
Source: Drug Industry Daily